Although unsaturated C16:l and saturated C16:0 monoglycerides were not as potent as C18:1 monoglyceride, they nevertheless can kill B-CLL
cells while sparing normal PBMCs under the same doses and conditions.
We are excited to be entering an era where our improved understanding of B-CLL
, coupled with more advanced laboratory tests and targeted therapy options like Campath, has dramatically changed the first-line treatment approach for this type of leukemia.
We analyzed U937 and Jurkat cell culture samples and whole-blood samples from 10 healthy donors, 26 B-CLL
patients, and 13 myeloid neoplasia patients.
Although the precise biologic mechanism of B-CLL
is still unclear, several prosurvival signaling molecules have been implicated, including Bcl-2, Akt, and ERK.
In all patients, the diagnosis of B-CLL
was confirmed by immunophenotyping by flow cytometry of peripheral blood in 1999 or 2000 (performed by Impath, New York, NY).
is a blood disorder in which abnormal B-lymphocytes (white blood cells) build up in the bone marrow, blood and organs of the body, causing infection, bone marrow dysfunction and enlargement of the lymph nodes, liver and spleen.
is the most common form of leukemia in adults in western countries.
In addition, it was observed that 26 percent (9 out of 34) of complete responders in the Campath arm achieved an MRD (minimal residual disease) negative response as defined by testing below the level of B-CLL
(c) (bone marrow transplantation) 9 Negative SSA (38.
Flow cytometry revealed no B-CLL
cells in the peripheral blood and less than 2% B-CLL
cells in the bone marrow.
We describe a patient with B-CLL
whose B cells expressed CD8, a predominantly T-cell marker also expressed in natural killer cells, and we propose that patients with this uncommon feature of B-CLL
might have an increased sensitivity to fludarabine phosphate, a substance recently often used to treat patients with CLL.
To exclude possible B-CLL
propagating effects, we analysed the in vitro reactions of cultured peripheral blood B-CLL
cells from patients receiving VA-E subcutaneously.